{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Zhang X"],"funding":["Chongqing Jingyin Bioscience Co., Ltd.","Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences","Ministry of Science and Technology of the People&apos;s Republic of China","Beijing Municipal Science and Technology Commission, Adminitrative Commission of Zhongguancun Science Park","Chinese Stroke Association","National Natural Science Foundation of China","Salubris","Capital&apos;s Funds for Health Improvement and Research","National Science and Technology Major Project"],"pagination":["541-550"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11732837"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["9(5)"],"pubmed_abstract":["<h4>Objectives</h4>Evidence of the optimal antiplatelet therapy for elderly patients who had a stroke is limited, especially those elder than 80 years. This study aimed to explore the efficacy and safety of dual antiplatelet therapy (DAPT) in old-old patients compared with younger patients in the ticagrelor or Clopidogrel with aspirin in High-risk patients with Acute Non-disabling Cerebrovascular Events-II (CHANCE-2) trial.<h4>Methods</h4>CHANCE-2 was a randomised, double-blind, placebo-controlled trial in China involving patients with high-risk transient ischaemic attack or minor stroke with CYP2C19 loss-of-function alleles. In our substudy, all enrolled patients were stratified by age: old-old (≥80 years), young-old (65-80 years) and younger (<65 years). The primary outcomes were stroke "],"journal":["Stroke and vascular neurology"],"pubmed_title":["Efficacy and safety of dual antiplatelet therapy in the elderly for stroke prevention: a subgroup analysis of the CHANCE-2 trial."],"pmcid":["PMC11732837"],"funding_grant_id":["2020-1-2041","81870905","2017ZX09304018","U20A20358","82101357","2019-I2M-5-029"],"pubmed_authors":["Li H","Jing J","Li J","Wang A","Liu L","Xie X","Xu Q","Han X","Johnston SC","Gong X","Meng X","Zhao X","Jiang Y","Li Z","Zhang X","Chen W","Bath PM","Lin J","Wang Y"],"additional_accession":[]},"is_claimable":false,"name":"Efficacy and safety of dual antiplatelet therapy in the elderly for stroke prevention: a subgroup analysis of the CHANCE-2 trial.","description":"<h4>Objectives</h4>Evidence of the optimal antiplatelet therapy for elderly patients who had a stroke is limited, especially those elder than 80 years. This study aimed to explore the efficacy and safety of dual antiplatelet therapy (DAPT) in old-old patients compared with younger patients in the ticagrelor or Clopidogrel with aspirin in High-risk patients with Acute Non-disabling Cerebrovascular Events-II (CHANCE-2) trial.<h4>Methods</h4>CHANCE-2 was a randomised, double-blind, placebo-controlled trial in China involving patients with high-risk transient ischaemic attack or minor stroke with CYP2C19 loss-of-function alleles. In our substudy, all enrolled patients were stratified by age: old-old (≥80 years), young-old (65-80 years) and younger (<65 years). The primary outcomes were stroke ","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Nov","modification":"2026-06-01T09:00:04.957Z","creation":"2025-04-06T01:14:10.607Z"},"accession":"S-EPMC11732837","cross_references":{"pubmed":["38286485"],"doi":["10.1136/svn-2023-002450"]}}